Suitability of the hybrid molecule PSMA-914 for nuclear medicine diagnostics and intraoperative, fluorescence-guided navigation in prostate carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028556

Enrollment

Registered

2022-04-08

Start date

2022-04-08

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Patients with primary diagnosis of high-risk prostatate cancer (retrospective data analysis)

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Men with a newly diagnosed, histologically confirmed prostate carcinoma with a high-risk profile before a planned operation who had participated in the treatment trial with PSMA-914 and who had consented to an evaluation of the pre-, intra- and postoperative data analysis.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Description of the use of the hybrid molecule PSMA-914 for preoperative and intraoperative diagnostics in prostate cancer (user reality/feasibility analysis).	—

Secondary

Measure	Time frame
Analysis of the results of the pre- and intraoperative imaging and correlation with the histopathological evaluation	—

Countries

Germany

Contacts

Public ContactJuri Ruf

University Clinic Freiburg / Department of Nuclear Medicine

juri.ruf@uniklinik-freiburg.de0761 270-39990

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026